Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Betere bestraling van slokdarmkanker
mei 2020 | Chirurgie, Maag-darm-leveroncologie, Radiotherapie